Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Cytarabine liposome |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing capecitabine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
pyrimidinanalog |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
1 |
Capecitabine 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Capecitabine 150 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing tegafur and uracil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Tegafur 100 mg and uracil 224 mg oral capsule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 100 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 100 mg/ml injektionsvæske, opløsning, hætteglas a 20 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 20 mg/ml injektionsvæske, opløsning, hætteglas a 25 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 1 g pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 20 mg/ml injektionsvæske, opløsning 5ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 100 mg/ml injektionsvæske, opløsning, hætteglas a 1 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 100 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 100 mg pulver til injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing precisely cytarabine 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Cytarabine 500mg/vial injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Cytarabine 1g/vial injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Cytarabine 2g/vial injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Cytarabine 10mg/mL suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
liposomalt cytarabin 50 mg/5 ml injektionsvæske, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Gemcitabine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Fluorouracil (substance) |
Is a |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Floxuridine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing cytarabine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 500 mg pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 1 g/pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
cytarabin 2 g/pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing precisely cytarabine 50 milligram/1 milliliter conventional release suspension for injection (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Product containing azacitidine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
azacitidin 100 mg pulver til injektionsvæske, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Azacitidine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Capecitabine (substance) |
Is a |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Cytarabine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Tegafur (substance) |
Is a |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Uracil |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Decitabine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Fluorouracil sodium |
Is a |
False |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Fluorouracil (18-F) (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Gemcitabine hydrochloride (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|
Fluoropyrimidine (substance) |
Is a |
True |
Pyrimidine analog (substance) |
Inferred relationship |
Some |
|